Endometrial Cancer Market Size & Growth Forecast 2027–2036, By Segments (Type of Cancer, Type of Therapy, Diagnosis Method), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Endometrial Cancer Market size was around USD 30.71 billion in 2026 and is slated to grow at a 5.22% CAGR from 2027 to 2036, reaching USD 51.08 billion by 2036. The industry revenue for 2027 is estimated at USD 32.22 billion.
Get more details on this report
Request Free Sample ReportEndometrial Cancer Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with established oncology pathways, strong diagnostic access, and structured referral systems that enable timely detection and treatment across advanced healthcare networks.
- Asia Pacific is growing at a 6.55% CAGR due to improving cancer diagnosis access, expanding hospital infrastructure, and increasing patient entry into formal oncology treatment systems.
Segment Momentum
- Chemotherapy leads the market because of its established role in systemic disease control, broad physician familiarity, and routine use in advanced and recurrent cases across conventional treatment pathways.
- Uterine Serous Carcinoma is the fastest-growing segment because increasing focus on aggressive, high-risk disease requires more specialized treatment planning and greater therapeutic engagement than routinely managed subtypes.
Market Expansion Drivers
- Rising incidence of endometrial cancer increasing demand for advanced therapeutic and diagnostic solutions.
- Growing adoption of personalized medicines and targeted oncology therapies strengthening treatment innovation.
- Expanding cancer awareness initiatives improving early screening and patient treatment engagement.
Leading Market Participants
- Key players in the endometrial cancer market include Bristol-Myers Squibb Company (U.S.), Pfizer Inc. (U.S.), Elekta AB (Sweden), Siemens Healthineers AG (Germany), Merck & Co., Inc. (U.S.), AstraZeneca PLC (U.K.), Johnson & Johnson (U.S.), Karyopharm Therapeutics Inc. (U.S.), R-Pharm-US LLC (U.S.), Sysmex Corporation (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 30.71 billion
- 2027 Estimated Market Size: USD 32.22 billion.
- Projected Market Size: USD 51.08 billion by 2036
- Growth Forecast: 5.22% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Endometrioid Adenocarcinoma (Type of Cancer) | Chemotherapy (Type of Therapy) | Biopsy (Diagnosis Method)
- Emerging Opportunity Segment: Uterine Serous Carcinoma (Type of Cancer) | Hormone Therapy (Type of Therapy) | Hysteroscopy (Diagnosis Method)
Market Growth Drivers and Industry Trends
Rising incidence of endometrial cancer increasing demand for advanced therapeutic and diagnostic solutions
The increasing burden of endometrial cancer will drive the endometrial cancer market as healthcare systems require more effective approaches for disease detection, characterization, and treatment. Rising patient numbers are increasing demand for diagnostic evaluations that can distinguish disease characteristics and guide treatment decisions, alongside therapeutic options for localized and advanced disease. Greater clinical attention to disease staging, recurrence risk, and treatment response is encouraging the use of specialized diagnostics and oncology therapies across multidisciplinary care pathways.
Growing adoption of personalized medicines and targeted oncology therapies strengthening treatment innovation
Personalized treatment approaches are transforming the endometrial cancer market by enabling therapies to be selected according to tumor characteristics and molecular profiles. Advances in genomic and biomarker testing can help identify patients who may benefit from specific targeted or immune-based treatments, reducing reliance on uniform treatment strategies. Pharmaceutical and clinical research efforts are increasingly focused on identifying actionable biological features within endometrial tumors, supporting the development and use of therapies tailored to distinct disease subtypes and patient responses.
Expanding cancer awareness initiatives improving early screening and patient treatment engagement
Cancer awareness programs are supporting the endometrial cancer market by encouraging individuals to recognize potential symptoms and seek medical evaluation earlier. Improved awareness can increase engagement with healthcare providers and facilitate diagnostic assessment when abnormal bleeding or other warning signs appear, supporting earlier disease identification. Public education and patient outreach can also improve understanding of available treatment pathways, helping patients participate more actively in clinical decision-making and remain engaged throughout diagnosis, therapy, and follow-up care.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising incidence of endometrial cancer increasing demand for advanced therapeutic and diagnostic solutions | 1.90% | Moderate | North America, Europe, Asia Pacific | High | Near Term |
| Growing adoption of personalized medicines and targeted oncology therapies strengthening treatment innovation | 1.70% | High | North America, Europe | High | Mid Term |
| Expanding cancer awareness initiatives improving early screening and patient treatment engagement | 1.20% | Moderate | Asia Pacific, North America | Emerging | Near Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the endometrial cancer market in 2026, reflecting its advanced oncology care infrastructure, strong availability of diagnostic services, and high adoption of innovative cancer therapies. The region has well-developed capabilities in molecular testing, precision oncology, clinical research, and multidisciplinary cancer management, enabling broader use of targeted and personalized treatment approaches. Greater awareness of women's health and cancer screening, combined with established healthcare systems and access to specialized oncology services, supports demand for advanced diagnosis and treatment. Continued progress in biomarker-driven therapy, immunotherapy, and molecular characterization is further strengthening the regional market by expanding therapeutic options and improving the ability to tailor treatment strategies to individual patients.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing regional market, supported by expanding healthcare infrastructure, improving cancer diagnosis, and increasing access to specialized oncology treatment. Rising healthcare expenditure and greater awareness of women's cancers are encouraging earlier diagnosis and broader engagement with formal healthcare services. Improvements in pathology, molecular diagnostics, imaging, and oncology treatment capabilities are also enabling healthcare providers to identify and manage endometrial cancer more effectively. In addition, the gradual expansion of specialized cancer centers and growing adoption of precision medicine are creating a stronger foundation for advanced therapies. Increasing healthcare accessibility across emerging economies, together with greater clinical focus on personalized cancer management, is expected to sustain strong market momentum across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Guideline-Based TreatmentGermany prioritizes evidence-based treatment pathways and multidisciplinary cancer care, encouraging adoption of advanced therapeutic options for endometrial cancer. The country's focus on standardized clinical practice supports demand for innovative oncology medicines with demonstrated clinical value.
France 🇫🇷
Coordinated Cancer CareFrance emphasizes coordinated oncology care and structured treatment pathways for patients with endometrial cancer. The country's focus on integrating innovative medicines into established clinical protocols creates opportunities for therapies demonstrating meaningful therapeutic benefit.
Italy 🇮🇹
Hospital-Centered AdoptionItaly relies on specialized oncology centers to drive adoption of advanced endometrial cancer treatments, with purchasing decisions often influenced by regional healthcare systems. Growing use of molecular testing supports broader consideration of targeted therapeutic options.
Japan 🇯🇵
Personalized Therapy IntegrationJapan is expanding the incorporation of biomarker-guided treatment strategies for endometrial cancer while maintaining careful evaluation of clinical outcomes. Local clinical evidence and specialist oncology centers play an important role in supporting adoption of newer therapeutic approaches.
South Korea 🇰🇷
Innovation-Focused OncologySouth Korea is strengthening access to advanced oncology treatments through active clinical research and increasing use of precision diagnostics for endometrial cancer. Collaboration between hospitals and pharmaceutical companies supports continued introduction of innovative therapies into clinical practice.
United States 🇺🇸
Precision Oncology AdoptionThe U.S. continues to emphasize molecular profiling and biomarker-driven treatment pathways for endometrial cancer, supporting broader use of targeted therapies and immunotherapies. Ongoing clinical research and integration into oncology practice strengthen commercial opportunities across the treatment continuum.
Segment Leadership and Growth Trends
Endometrial Cancer Market Share (%), by Type of Cancer, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType of Cancer Segment Analysis: Endometrioid Adenocarcinoma (Largest Segment) vs Uterine Serous Carcinoma (Fastest-Growing Segment)
The endometrioid adenocarcinoma segment led the endometrial cancer market in 2026, supported by its established clinical prevalence and its strong association with hormone-related and metabolic risk factors. This histological subtype is commonly identified through routine diagnostic evaluation of endometrial abnormalities, creating sustained demand for diagnostic testing, pathology services, and treatment interventions. Its established treatment pathways, encompassing surgery and systemic or hormone-based approaches according to disease characteristics, further contribute to its dominant position. Continued emphasis on early detection of abnormal uterine bleeding and improved diagnostic assessment also supports the segment's broad clinical relevance.
Uterine serous carcinoma is the fastest-growing cancer type segment, driven by the clinical need to address this aggressive form of endometrial cancer and its distinct therapeutic requirements. Greater recognition of high-risk histological subtypes is encouraging more precise pathological classification and treatment planning. Advances in molecular characterization and the increasing use of personalized approaches are also supporting research and therapeutic development focused on aggressive endometrial tumors. As healthcare providers place greater emphasis on risk stratification and targeted management, demand for specialized diagnostic and treatment solutions for uterine serous carcinoma is gaining momentum.
Type of Therapy Segment Analysis: Chemotherapy (Largest Segment) vs Hormone Therapy (Fastest-Growing Segment)
Chemotherapy accounted for the largest position in the endometrial cancer market in 2026, reflecting its established role in managing advanced, recurrent, or high-risk disease. Systemic chemotherapy remains an important treatment option when cancer has progressed beyond localized disease or requires broader therapeutic intervention. Its integration into multimodal treatment strategies, including combinations with surgery, radiation, or other systemic approaches, supports continued utilization across appropriate patient populations. Ongoing improvements in cancer diagnosis and treatment planning further strengthen the role of chemotherapy within the overall therapeutic landscape.
The hormone therapy segment is advancing at the fastest pace as treatment strategies increasingly incorporate tumor biology and hormone sensitivity into therapeutic decision-making. Hormonal approaches can provide a less intensive systemic treatment option for selected patients, particularly when tumors demonstrate hormone responsiveness or when preservation of quality of life is an important consideration. Growing interest in individualized treatment pathways and the identification of patients who may benefit from endocrine-based interventions are supporting wider adoption. Research into hormone-responsive disease and improved patient selection is further strengthening the growth prospects of this therapy segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type of Cancer | Endometrioid Adenocarcinoma, Uterine Serous Carcinoma, Others | Endometrioid Adenocarcinoma | Uterine Serous Carcinoma |
| Type of Therapy | Chemotherapy, Radiation Therapy, Hormone Therapy, Others | Chemotherapy | Hormone Therapy |
| Diagnosis Method | Biopsy, Imaging, Hysteroscopy, Others | Biopsy | Hysteroscopy |
Competitive Landscape and Market Positioning
Top players in the endometrial cancer market:
1. Bristol-Myers Squibb Company (U.S.)
2. Pfizer Inc. (U.S.)
3. Elekta AB (Sweden)
4. Siemens Healthineers AG (Germany)
5. Merck & Co. Inc. (U.S.)
6. AstraZeneca PLC (U.K.)
7. Johnson & Johnson (U.S.)
8. Karyopharm Therapeutics Inc. (U.S.)
9. R-Pharm-US LLC (U.S.)
10. Sysmex Corporation (Japan)
The endometrial cancer market is evolving through precision medicine and targeted therapy advancements. Innovation is improving treatment efficacy and patient survival outcomes. Collaborative research efforts are accelerating therapeutic development. Continuous development is strengthening oncology treatment pipelines.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (U.S.) | |||||||
| Pfizer Inc. (U.S.) | |||||||
| Elekta AB (Sweden) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Merck & Co. Inc. (U.S.) | |||||||
| AstraZeneca PLC (U.K.) | |||||||
| Johnson & Johnson (U.S.) | |||||||
| Karyopharm Therapeutics Inc. (U.S.) | |||||||
| R-Pharm-US LLC (U.S.) | |||||||
| Sysmex Corporation (Japan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Merck & Co. | May-26 | Merck and Kelun Biotech announced that their phase 3 clinical trial of the TROP2 antibody-drug conjugate, sacituzumab tirumotecan, met primary endpoints in endometrial cancer. The study demonstrated significant survival benefits in late-stage disease settings, validating the therapeutic candidate's efficacy and strengthening Merck's oncology pipeline while positioning the drug for potential regulatory submission and market entry. |
| Utepreva LLC | Apr-26 | Utepreva introduced an FDA-cleared endometrial sampling device utilizing advanced suction and tissue disruption technology to enhance cancer detection. By enabling rapid, office-based procedures with superior tissue yield, the device addresses clinical workflow inefficiencies and supports earlier diagnostic accuracy, representing a meaningful technological advancement in the diagnostic value chain for gynecologic oncology. |
| Acrivon Therapeutics | Jan-26 | Acrivon Therapeutics reported positive results from a registrational-intent Phase 2b trial of ACR-368 in biomarker-positive patients. Demonstrating robust monotherapy activity in endometrial cancer, these findings support the candidate’s regulatory advancement as a precision oncology treatment, targeting a specific patient population and potentially expanding the available therapeutic options for difficult-to-treat endometrial malignancy. |
| GSK | Sep-25 | GSK secured reimbursement approval in Korea for Jemperli (dostarlimab) as a first-line treatment for advanced endometrial cancer in combination with chemotherapy. This milestone enhances the drug's competitive positioning, increases patient access, and reinforces Jemperli’s status as a foundational immunotherapy in the frontline management of gynecologic oncology, directly influencing treatment standard-of-care patterns in the region. |
| Biocartis | Apr-25 | Biocartis launched a real-time qPCR assay designed to target POLE and POLD1 mutations, facilitating improved molecular profiling for patient stratification in endometrial cancer. By enabling precise identification of clinically relevant genetic alterations, the diagnostic tool supports personalized treatment decision-making and enhances clinical efficiency, marking a strategic expansion in molecular diagnostic capabilities for gynecologic cancer management. |
| Sysmex Corporation | Oct-22 | Sysmex Corporation received authorization for a modification to its LYNOAMP CK19 gene amplification component, expanding its clinical application to include testing for endometrial and cervical cancers. This regulatory milestone extends the utility of the diagnostic platform, enabling broader adoption of molecular testing in gynecologic oncology and strengthening the company’s position in the cancer diagnostic supply chain. |
| Karyopharm Therapeutics | Feb-22 | Karyopharm Therapeutics announced positive preliminary outcomes from a Phase 3 study evaluating Selinexor as a first-line maintenance therapy for advanced or recurrent endometrial cancer. The clinical progress of this candidate represents a critical step in addressing high-unmet medical needs within the disease area, with the potential to alter the therapeutic landscape for patients transitioning from initial treatment. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Endometrial Cancer Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Stage | Stage I, Stage II, Stage III, Stage IV |
| Treatment Line | First-Line Therapy, Second-Line Therapy, Third-Line Therapy, Later-Line Therapy |
| Biomarker Status | Mismatch Repair Deficient/Microsatellite Instability-High, Mismatch Repair Proficient/Microsatellite Stable, POLE-Mutated, TP53-Abnormal |
Endometrial Cancer Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Biomarker Testing and Companion Diagnostics Landscape |
|
| Patient Journey and Treatment Pathway Assessment |
|
| Gynecologic Oncology Center Excellence Mapping |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of endometrial cancer?
What is the projected value of the endometrial cancer industry by 2036?
How is rising endometrial cancer incidence reshaping demand for diagnostics and treatment solutions?
What role is personalized medicine playing in the evolution of treatment strategies in endometrial cancer care?
Why is Chemotherapy the largest therapy segment in the endometrial cancer market?
Why is Uterine Serous Carcinoma the fastest-growing cancer type segment in the endometrial cancer market?
Why does North America hold the largest share of the endometrial cancer market?
What is supporting the fastest growth of the endometrial cancer market in Asia Pacific?
Which companies dominate the endometrial cancer landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization